| Dr Justin Matthias Hintze, MD MSC | |
|
300 Longwood Ave, Boston, MA 02115-5724 | |
| (617) 355-6000 | |
| Not Available |
| Full Name | Dr Justin Matthias Hintze |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Location | 300 Longwood Ave, Boston, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104423680 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 414909 (ZZ) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Justin Matthias Hintze, MD MSC 35 Victoria Street, Dublin, DUBLIN DUBLI-N8 Ph: () - | Dr Justin Matthias Hintze, MD MSC 300 Longwood Ave, Boston, MA 02115-5724 Ph: (617) 355-6000 |
News Archive
Most of the tests that doctors use to diagnose cancer - such as mammography, colonoscopy, and CT scans - are based on imaging. More recently, researchers have also developed molecular diagnostics that can detect specific cancer-associated molecules that circulate in bodily fluids like blood or urine.
Onyx Pharmaceuticals, Inc. today announced that it has filed a complaint in the United States District Court for the Northern District of California asserting its rights to a Phase 2 anti-cancer compound discovered during joint research between Onyx and Bayer.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has submitted a study protocol to the U.S. Food and Drug Administration for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.
› Verified 1 days ago
Dr. Steven D. Rauch, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-523-7900 | |
Elliott D. Kozin, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-6545 | |
Katherine Nicole Vandenberg, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 830 Harrison Ave Ste 1400, Boston, MA 02118 Phone: 617-638-8124 | |
Yoon Sun Chun, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Brigham And Women's Hospital Dept Of Plastic Surgery, Boston, MA 02115 Phone: 617-732-8181 Fax: 617-983-4534 | |
Jaimie Derosa, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 91 Newbury St, Suite 300, Boston, MA 02116 Phone: 617-262-8000 Fax: 617-262-8002 | |
Dr. Usama M Aboelkheir, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 736 Cambridge St, Smc8, Boston, MA 02135 Phone: 617-789-5004 Fax: 617-779-6481 | |
Phillip C Song, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-3557 |